Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

CASI Pharmaceuticals Inc

CASI
Current price
3.43 USD -0.31 USD (-8.29%)
Last closed 3.63 USD
ISIN US14757U1097
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 86 582 160 USD
Yield for 12 month -52.49 %
1Y
3Y
5Y
10Y
15Y
CASI
21.11.2021 - 28.11.2021

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc"RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China. Address: 1701-1702, China Central Office Tower 1, Beijing, China, 100025

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

6 USD

P/E ratio

Dividend Yield

Current Year

+33 879 000 USD

Last Year

+43 107 000 USD

Current Quarter

+7 793 000 USD

Last Quarter

+3 979 000 USD

Current Year

+20 052 000 USD

Last Year

+27 280 000 USD

Current Quarter

+4 045 000 USD

Last Quarter

+2 067 000 USD

Key Figures CASI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -23 079 500 USD
Operating Margin TTM -240.11 %
PE Ratio
Return On Assets TTM -26.6 %
PEG Ratio
Return On Equity TTM -85.43 %
Wall Street Target Price 6 USD
Revenue TTM 23 100 000 USD
Book Value 0.67 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -59.5 %
Dividend Yield
Gross Profit TTM 17 611 000 USD
Earnings per share -2.03 USD
Diluted Eps TTM -2.03 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -117.68 %

Dividend Analytics CASI

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CASI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 02.06.2022
Dividend Date

Stock Valuation CASI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.468
Price Sales TTM 2.6036
Enterprise Value EBITDA 0.0687
Price Book MRQ 4.0531

Financials CASI

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CASI

For 52 weeks

2.05 USD 8.19 USD
50 Day MA 6.05 USD
Shares Short Prior Month 75 573
200 Day MA 5 USD
Short Ratio 2.36
Shares Short 44 884
Short Percent 0.69 %